###begin article-title 0
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 78 81 78 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 271 278 <span type="species:ncbi:9606">patient</span>
Single-nucleotide polymorphisms (SNPs) in codon 72 of the TP53 (also known as p53) gene (rs1042522) and in the promoter region of the MDM2 gene (SNP309; rs2279744) have been suggested to play roles in many cancers. We investigated whether these SNPs were associated with patient outcome and the effect of adjuvant systemic therapy.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
The genotypes of TP53 codon 72 and MDM2 SNP309 were defined among 557 primary Japanese breast cancer patients (median follow-up, 61.7 months). The effects of several variables on survival were tested by Cox's proportional hazards regression analysis.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 155 157 155 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 231 233 231 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 284 289 284 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 363 368 363 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 468 470 468 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 588 593 588 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 423 431 <span type="species:ncbi:9606">patients</span>
###xml 503 511 <span type="species:ncbi:9606">patients</span>
We showed that the Pro/Pro genotype of TP53 codon 72 was associated with poorer disease-free survival (DFS) than other genotypes by Kaplan-Meier analysis (P = 0.049) and multivariate Cox's proportional hazards regression analysis (P = 0.047, risk ratio of recurrence = 1.67), whereas MDM2 SNP309 status was not associated with DFS. The association of the Pro/Pro TP53 genotype with poorer DFS was especially significant in patients who received adjuvant chemotherapy (P = 0.009). In contrast, among the patients who had received adjuvant hormonal therapy or no adjuvant systemic therapy, TP53 codon 72 genotype was not associated with DFS.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
The Pro/Pro genotype of TP53 codon 72 appears to be an independent prognostic marker in breast cancer patients.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 161 162 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 205 210 205 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 339 340 339 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 433 434 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 549 550 549 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 607 608 607 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 609 610 609 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 500 515 <span type="species:ncbi:10090">transgenic mice</span>
###xml 568 573 <span type="species:ncbi:9606">human</span>
The TP53 tumor suppressor pathway is well-known to be crucial for maintaining genomic integrity and preventing cells from undergoing oncogenic transformation [1,2]. MDM2 plays a key role in regulating the TP53 pathway by binding directly to the p53 protein, inhibiting its activity and mediating degradation via the ubiquitination system [3]. p53 also positively regulates MDM2 expression, thereby creating a negative feedback loop [3]. Overexpression of MDM2 is observed both in epithelial cells of transgenic mice with induced mammary carcinomas [4] and in multiple human tumors, including breast cancer [5-7].
###end p 11
###begin p 12
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 28 29 28 29 <underline xmlns:xlink="http://www.w3.org/1999/xlink">G</underline>
###xml 35 36 35 36 <underline xmlns:xlink="http://www.w3.org/1999/xlink">C</underline>
###xml 63 64 63 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 414 415 414 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 528 529 528 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 639 641 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 685 690 685 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 762 764 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 811 816 811 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 947 949 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1051 1056 1051 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1085 1087 1085 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1088 1090 1088 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1251 1253 1251 1253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1314 1316 1314 1316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1570 1572 1570 1572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1705 1707 1705 1707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1760 1765 1760 1765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1860 1865 1860 1865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1921 1923 1921 1923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 647 655 <span type="species:ncbi:9606">Patients</span>
###xml 870 878 <span type="species:ncbi:9606">patients</span>
###xml 974 982 <span type="species:ncbi:9606">patients</span>
###xml 1013 1021 <span type="species:ncbi:9606">patients</span>
###xml 1134 1142 <span type="species:ncbi:9606">patients</span>
###xml 1370 1378 <span type="species:ncbi:9606">patients</span>
###xml 1552 1560 <span type="species:ncbi:9606">patients</span>
###xml 1668 1673 <span type="species:ncbi:9606">women</span>
The TP53 codon 72 Arg>Pro (CGC to CCC) polymorphism of exon 4 [8] (National Center for Biotechnology Information single-nucleotide polymorphism (SNP) identification number rs1042522) has been suggested to play a role in several different cancer types. These two variant protein forms may behave differently, as the Arg/Arg genotype has been reported to induce apoptosis more effectively than the Pro/Pro genotype [9,10], which may be due to enhanced mitochondrial localization of p53 protein in cells with the Arg/Arg genotype [9]. In contrast, the Pro/Pro genotype appears to induce a higher level of G1 arrest than the Arg/Arg genotype [11,12]. Patients with the Pro/Pro genotype of TP53 in breast cancers have poorer survival than those with other genotypes [13]. Furthermore, retention of the Arg allele of TP53 in tumor tissue of Arg/Pro heterozygous breast cancer patients has been associated with reduced disease-free and overall survival [14]. Taiwanese lung cancer patients and Israeli colorectal cancer patients with the Pro/Pro genotype of TP53 also showed poorer survival [15,16]. A recent study showed that breast cancer patients with the Pro/Pro genotype were less sensitive to chemotherapy than those with Arg/Arg or Arg/Pro genotypes [17]. Similar results were reported in head and neck carcinoma [11]. On the other hand, estrogen receptor (ER) positive patients possessing the Pro allele had better distant recurrence-free survival when randomized to tamoxifen compared to those who did not receive tamoxifen, while homozygous Arg/Arg patients did not [18]. After the initial report of a statistically significantly increased risk of breast cancer in women homozygous for the Pro allele [19], numerous studies examined a possible role of this TP53 polymorphism in breast cancer risk. Meta-analysis of nine studies has recently shown that this TP53 polymorphism is not associated with breast cancer risk [20].
###end p 12
###begin p 13
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 182 184 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 191 196 189 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 261 263 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 343 348 341 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 445 447 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 551 553 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 630 635 628 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 714 719 712 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 720 722 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 820 822 818 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 823 825 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 941 946 939 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 1028 1030 1026 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1114 1119 1112 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1225 1230 1223 1228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 1247 1252 1245 1250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1260 1262 1258 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 574 582 <span type="species:ncbi:9606">patients</span>
###xml 868 873 <span type="species:ncbi:9606">women</span>
###xml 1065 1073 <span type="species:ncbi:9606">patients</span>
A SNP in the promoter of the MDM2 gene, referred to as SNP309 (a T-->G change) (rs2279744), has been implicated in earlier age of onset of Li-Fraumeni syndrome and sporadic cancers [21]. The MDM2 SNP309 G/G homozygous genotype elevates MDM2 protein expression [21]. A recent study showed that cells that harbor this genotype had a compromised TP53 response pathway and formed transcriptionally inactive p53-MDM2 complexes in response to stress [22]. The G/G genotype was also associated with increased incidence of esophageal squamous cell carcinoma [23]. Colorectal cancer patients who had both the SNP309 G allele and wild-type TP53 were diagnosed at a younger age than those with the T/T genotype and wild-type TP53 [24]. On the other hand, no association was found between SNP309 status and breast cancer incidence [25-27]. However, a recent study showed that, in women whose breast cancers expressed high levels of ER, those having the MDM2 SNP309 G/G genotype showed earlier age of onset than those with the T/T genotype [28]. Another study showed that among patients with the T/T genotype, mutant status of TP53 and aberrant p53 protein expression were associated with poor survival, suggesting an interaction between MDM2 SNP309 and tumor TP53 status [25].
###end p 13
###begin p 14
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Here, we have examined germ-line DNA samples from 557 consecutive primary breast cancer patients to investigate the association between these SNPs and breast cancer prognosis.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
Study subjects
###end title 16
###begin p 17
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 221 229 <span type="species:ncbi:9606">patients</span>
###xml 464 472 <span type="species:ncbi:9606">patients</span>
###xml 518 526 <span type="species:ncbi:9606">patients</span>
###xml 771 779 <span type="species:ncbi:9606">patients</span>
###xml 1000 1008 <span type="species:ncbi:9606">patients</span>
###xml 1108 1116 <span type="species:ncbi:9606">patients</span>
###xml 1165 1173 <span type="species:ncbi:9606">Patients</span>
###xml 1375 1383 <span type="species:ncbi:9606">patients</span>
Blood samples were obtained from a total of 557 consecutive primary breast cancer patients at Nagoya City University Hospital, Nagoya, Japan, between January 1983 and December 2003. Informed consent was obtained from all patients before surgery. The histological grade was estimated according to the Bloom and Richardson method proposed by Elston and Ellis [29]. Treatment decisions were based on consensus recommendations at that time in Japan. After surgery, 77 patients received no adjuvant therapy. A total of 137 patients received adjuvant chemotherapy alone (64 received oral 5-fluorouracil (5-FU), 41 were treated with a CMF (cyclophosphamide/methotrexate/5-FU)-based regimen, 26 with an anthracycline-based regimen, and 6 received other regimens). A total of 195 patients received adjuvant hormonal therapy alone (157 received tamoxifen, 28 tamoxifen plus luteinizing hormone-releasing hormone (LH-RH) agonist, 5 were treated with LH-RH alone, and 5 with aromatase inhibitor). A total of 144 patients received a combination of hormonal therapy and chemotherapy. The adjuvant therapy received by four patients could not be determined due to missing records. Patients were followed postoperatively every three months for the first five years, then annually. The median follow-up period was 61.7 months (range 3 to 258 months). Relapse data were available in 497 of 557 patients examined: 105 (21.1%) experienced disease recurrence; 95 (19.1%) showed distant relapse; and 58 (11.6%) had died. This protocol was approved by the Institutional Review Board of Nagoya City University Graduate School of Medical Sciences.
###end p 17
###begin title 18
DNA extraction and genotyping
###end title 18
###begin p 19
###xml 146 151 146 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 164 169 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 256 261 256 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 514 519 514 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 608 613 608 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 808 813 808 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
Genomic DNA was isolated from peripheral blood lymphocytes using a phenol-chloroform extraction method. Samples of genomic DNA were genotyped for TP53 codon 72 and MDM2 SNP309 polymorphisms. Genotyping was performed using TaqMan SNP genotyping assays. One TP53 probe (CTGCTCCCCGCGTGGCCC) was labeled at the 5'-end with VIC (Applied Biosystems' proprietary dye) and at the 3'-end with TAMRA. The other (CTGCTCCCCCCGTGGCCC) was labeled at the 5'-end with 6-carboxyfluorescein (FAM) and at the 3'-end with TAMRA. The TP53 primers were: forward, 5'-ATGAAGCTCCCAGAATGC-3', and reverse, 5'-GCCGGTGTAGGAGCT-3'. One MDM2 probe (CGCTGCGGCGCGGGA) was labeled at the 5'-end with VIC and labeled at the 3'-end with TAMRA. The other (CCGCTTCGGCGCGGGA) was labeled at the 5'-end with FAM and at the 3'-end with TAMRA. The MDM2 primers used for genotyping and sequencing were: forward, 5'-ATTTCGGACGGCTCTCGC-3', and reverse, 5'-GCGCAGCGTTCACACTAGTG-3'. Real-time TaqMan PCR and genotyping analyses were performed on an Applied Biosystems 7500 real-time PCR system (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's standard PCR protocol. The results were analyzed on a 7500 real-time PCR system using the allelic discrimination assay program of Sequence Detection software version 1.3.1 (Applied Biosystems).
###end p 19
###begin title 20
DNA sequencing
###end title 20
###begin p 21
###xml 120 125 120 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 267 272 267 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
DNA sequencing was performed to confirm the results of TaqMan SNP genotyping assays. The primers used for sequencing of TP53 were: forward, 5'-CCCGGACGATATTGAACAATGG-3', and reverse, 5'-CAGAATGCAAGAAGCCCAGAC-3'. As mentioned above, the primers used for sequencing of MDM2 were the same as those utilized in the TaqMan genotyping assays. The PCR products were sequenced by an ABI PRISM 3100 Genetic Analyzer and analyzed by ABI SeqScape Software version 2.1.1 (Applied Biosystems).
###end p 21
###begin title 22
Immunohistochemical analysis for p53
###end title 22
###begin p 23
###xml 158 160 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 176 181 <span type="species:ncbi:10090">mouse</span>
Serial sections (4 mum) for p53 staining were prepared from 289 consecutive breast cancer tissue blocks from 1983 to 1999 at Nagoya City University Hospital [30]. A monoclonal mouse antihuman p53 protein antibody (PAb1801; Novocastra, Newcastle, UK) was used at a 1:50 dilution. Bound antibody was detected with a streptavidin-biotin system (SAB-PO kit; Nichirei Co., Inc., Tokyo, Japan). Immunostaining was scored after the entire slide had been evaluated by light microscopy. The expression status of p53 was assessed according to the estimated proportion of tumor cells displaying positive nuclear staining. Scoring criteria for p53 protein expression were as follows (in the form, proportion of nuclear staining = score): none = 0, <1/10 = 1, 1/10 to 1/2 = 2, and >1/2 = 3. Tumors with a score of 1 or greater were considered to be positive for p53 protein accumulation.
###end p 23
###begin title 24
Estrogen receptor measurement
###end title 24
###begin p 25
Frozen tissue specimens were analyzed for ER by an enzyme immunoassay using ER EIA 'Abbott' (Dinabot, Tokyo, Japan). The cut-off ER level was less than 13 fmol/mg protein.
###end p 25
###begin title 26
Statistical analyses
###end title 26
###begin p 27
###xml 240 245 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 257 262 257 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 321 323 319 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 639 641 637 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
All molecular and immunohistochemical analyses were performed blinded to clinical data. Statistical calculations were done with StatView-J 5.0 software (SAS Institute Inc., Cary, NC, USA). The relationship between the genotype frequency of TP53 codon 72 or MDM2 SNP309 and clinicopathological factors were assessed by chi2 and Fisher's exact probability tests. Disease-free survival (DFS) curves were generated by the Kaplan-Meier method and verified by the log-rank test. Cox's proportional hazards regression analysis was used for univariate and multivariate analyses of prognostic values. Differences were considered significant when a P value < 0.05 was obtained.
###end p 27
###begin title 28
Results
###end title 28
###begin title 29
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
Distributions of TP53 and MDM2 polymorphisms
###end title 29
###begin p 30
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 71 76 71 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 331 336 331 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 348 353 348 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 425 426 425 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 431 432 431 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
Each of the TP53 codon 72 genotypes (Arg/Arg, Arg/Pro, or Pro/Pro) and MDM2 SNP309 genotypes (T/T, T/G, or G/G) was clearly discriminated using TaqMan SNP genotyping assays. The allelic discrimination data from these assays were confirmed by direct sequencing of representative PCR products. We did not find an association between TP53 codon 72 or MDM2 SNP309 genotypes and clinicopathological features in our series (Tables 1 and 2).
###end p 30
###begin p 31
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
Association between TP53 codon 72 status and clinicopathological characteristics
###end p 31
###begin p 32
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aArg/Arg and Arg/Pro genotypes compared with Pro/Pro genotype. ER, estrogen receptor; IDC, invasive ductal carcinoma; IHC, immunohistochemistry; ILC, invasive lobular carcinoma.
###end p 32
###begin p 33
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
Association between MDM2 SNP309 status and clinicopathological characteristics
###end p 33
###begin p 34
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aT/T + T/G genotypes versus G/G genotype. ER, estrogen receptor; IDC, invasive ductal carcinoma; IHC, immunohistochemistry; ILC, invasive lobular carcinoma.
###end p 34
###begin title 35
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
TP53 and MDM2 genotypes and breast cancer survival
###end title 35
###begin p 36
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 200 205 200 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 306 308 306 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 383 385 383 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 474 475 474 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 526 531 526 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 689 694 689 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 934 939 934 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1002 1004 1002 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1019 1021 1019 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 1084 1089 1084 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1142 1144 1142 1144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1160 1162 1160 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1d</xref>
###xml 1366 1371 1366 1371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 738 746 <span type="species:ncbi:9606">patients</span>
###xml 796 804 <span type="species:ncbi:9606">patients</span>
###xml 992 1000 <span type="species:ncbi:9606">patients</span>
###xml 1041 1049 <span type="species:ncbi:9606">patients</span>
###xml 1200 1208 <span type="species:ncbi:9606">patients</span>
###xml 1272 1280 <span type="species:ncbi:9606">patients</span>
We investigated whether these SNPs were associated with breast cancer survival. We found no association between MDM2 SNP309 status and DFS, as shown in Figure 1a. In contrast, the Pro/Pro genotype of TP53 codon 72 was significantly associated with poor DFS by Kaplan-Meier analysis, as shown in Figure 1b (P = 0.049), and multivariate Cox's proportional hazards regression analysis (P = 0.047, risk ratio of recurrence = 1.67, 95% confidence interval = 1.01 to 2.76) (Table 3). Our data indicates that the Pro/Pro genotype of TP53 codon 72 is an independent prognostic marker in breast cancer. In this analysis, we combined the Arg/Arg homozygous and the Arg/Pro heterozygous genotypes of TP53 codon 72, because the survival curve of the patients with the Arg/Arg genotype was similar to that of patients with the Arg/Pro genotype (data not shown). When the analysis was stratified by nodal status, no significant association between TP53 codon 72 genotype and DFS was seen for node-negative patients (P = 0.95; Figure 1c). In node-positive patients, however, the Pro/Pro genotype of TP53 codon 72 was significantly associated with poor DFS (P = 0.004; Figure 1d). Only 85 (26%) of 321 node-negative patients had received chemotherapy while 151 (76%) of 198 node-positive patients had. Therefore, we analyzed the relationship between breast cancer survival and this TP53 polymorphism in subgroups based on the type of adjuvant therapy.
###end p 36
###begin p 37
Uni- and mutivariate Cox's model (disease-free survival) of prognostic factors
###end p 37
###begin p 38
CI, confidence interval; ER, estrogen receptor; IHC, immunohistochemistry; RR, risk ratio.
###end p 38
###begin p 39
###xml 114 118 114 118 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 118 123 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 141 145 141 145 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 145 150 145 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 183 187 183 187 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 231 235 231 235 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 281 286 281 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
Kaplan-Meier survival curves of breast cancer patients. Disease-free survival (DFS) among patients categorized by (a) MDM2 SNP309 status and (b) TP53 codon 72 status. DFS in patients (c) without axillary lymph node involvement and (d) with lymph node metastasis according to their TP53 codon 72 status. NS, not significant.
###end p 39
###begin title 40
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
TP53 and MDM2 genotypes and adjuvant systemic therapy
###end title 40
###begin p 41
###xml 9 18 9 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 156 157 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 518 523 518 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 689 691 689 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 842 844 842 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 860 862 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 1008 1010 1008 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1017 1019 1017 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1035 1037 1035 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 1053 1058 1053 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1184 1186 1184 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1193 1195 1193 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1210 1212 1210 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2c</xref>
###xml 1277 1279 1277 1279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1285 1287 1285 1287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1302 1304 1302 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2d</xref>
###xml 221 229 <span type="species:ncbi:9606">patients</span>
###xml 634 642 <span type="species:ncbi:9606">patients</span>
###xml 941 949 <span type="species:ncbi:9606">patients</span>
###xml 1110 1118 <span type="species:ncbi:9606">patients</span>
Previous in vitro studies showed that cells with the TP53 codon 72 Arg/Arg genotype induced apoptosis markedly better than those with the Pro/Pro genotype [9,11]. A recent clinical study also suggested that breast cancer patients with the Pro/Pro genotype might be less sensitive to neoadjuvant chemotherapy than those with the Arg/Arg or Arg/Pro genotype [17]. Therefore, we hypothesized that this polymorphism might alter the sensitivity of tumors to adjuvant therapeutic agents. We analyzed the association between TP53 codon 72 polymorphism and DFS under different types of adjuvant systemic therapy. Our results show that, among patients who had received adjuvant chemotherapy alone (n = 137), those with the Pro/Pro genotype had poorer DFS than those with the Arg/Arg or Arg/Pro genotype, according to a Kaplan-Meier survival analysis (P = 0.009; Figure 2a). Similar results were observed when the analysis was expanded to include all patients receiving chemotherapy, with or without hormonal therapy (n = 281, P = 0.007; Figure 2b). In contrast, TP53 codon 72 genotype was not associated with DFS among patients who had received adjuvant hormonal therapy without chemotherapy (n = 195, P = 0.58; Figure 2c) nor among those who had received no adjuvant systemic therapy (n = 77, P = 0.24; Figure 2d).
###end p 41
###begin p 42
###xml 79 83 79 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 130 132 130 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 140 144 140 144 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 144 149 144 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 218 220 218 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 228 232 228 232 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 232 237 232 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 283 285 283 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 293 297 293 297 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 297 302 297 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 345 347 345 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 354 358 354 358 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 358 363 358 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 455 457 455 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
The effect of adjuvant systemic therapy on prognostic impact of polymorphisms. (a) TP53 codon 72 and adjuvant chemotherapy alone (n = 137); (b) TP53 codon 72 and adjuvant chemotherapy with or without hormonal therapy (n = 281); (c) TP53 codon 72 and adjuvant hormonal therapy alone (n = 195); (d) TP53 codon 72 and no adjuvant systemic therapy (n = 77); (e) MDM2 SNP309 and adjuvant tamoxifen with or without luteinizing hormone-releasing hormone analog (n = 185). DFS, disease-free survival.
###end p 42
###begin p 43
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 302 307 302 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2e</xref>
###xml 567 569 567 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 655 660 655 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 331 339 <span type="species:ncbi:9606">patients</span>
A recent study proposed a model in which an estrogen-signaling pathway allows the G-allele of MDM2 SNP309 to accelerate breast cancer formation [28]. We hypothesized that this allele might also alter the sensitivity of tumors to adjuvant hormonal therapy. We therefore examined the correlation between MDM2 SNP309 and prognosis in patients who received adjuvant tamoxifen with or without LH-RH agonist. Although the T/T genotype tended to be associated with better DFS compared to other genotypes of SNP309 (Figure 2e), this association did not achieve significance (P = 0.09), and no statistically significant correlation was found between prognosis and MDM2 SNP309 genotype.
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 141 146 141 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 242 247 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
We demonstrate here that SNPs of TP53 codon 72 may have an important role in breast cancer. We show that the Pro/Pro genotype at codon 72 of TP53 was associated with poor DFS, particularly in patients who received adjuvant chemotherapy while MDM2 SNP309 was not associated with prognosis.
###end p 45
###begin p 46
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 156 160 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 298 303 298 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 407 412 407 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 470 472 470 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 573 578 573 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 591 596 591 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 806 808 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 998 1003 998 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1122 1124 1122 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1222 1227 1222 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1364 1369 1364 1369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1406 1408 1406 1408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 373 381 <span type="species:ncbi:9606">patients</span>
###xml 1061 1069 <span type="species:ncbi:9606">patients</span>
###xml 1277 1285 <span type="species:ncbi:9606">patients</span>
###xml 1321 1329 <span type="species:ncbi:9606">patients</span>
TP53 codon 72 encodes two distinct functional allelic forms: arginine (Arg) or proline (Pro) [8]. Polymorphism at this codon has been suggested to modulate TP53-dependent apoptosis and modify sensitivity to chemotherapeutic agents [9,11,12,17]. Recent studies reported that the Pro/Pro genotype of TP53 codon 72 was associated with poorer survival in Finnish breast cancer patients [13], and suggested that MDM2 SNP309 status is associated with p53 protein function [21,22]. These findings inspired us to investigate the association of breast cancer prognosis with SNPs of TP53 codon 72 and MDM2 SNP309. We used the TaqMan SNP genotyping assay, which is amenable to high-throughput genotyping and avoids many problems of traditional genotyping assays, such as PCR-restriction fragment length polymorphism [31]. Although the TaqMan assay is convenient and reliable, it is less accurate than direct sequencing. Therefore, we analyzed our data carefully. Our results show that the Pro/Pro genotype of TP53 was associated with poorer DFS in Japanese breast cancers patients, thus supporting the Finnish study mentioned above [13]. However, the authors of that study did not address the question of why the Pro/Pro genotype of TP53 adversely affected the prognosis of breast cancer patients. Analysis of our entire set of 557 patients showed a relationship between the TP53 Pro/Pro genotype and DFS, but with a P value (0.047) at the borderline of significance, leaving doubt as to whether the Pro/Pro genotype is an independent risk factor for poor DFS.
###end p 46
###begin p 47
###xml 72 77 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 361 366 361 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 149 157 <span type="species:ncbi:9606">patients</span>
###xml 467 475 <span type="species:ncbi:9606">patients</span>
###xml 588 596 <span type="species:ncbi:9606">patients</span>
###xml 623 631 <span type="species:ncbi:9606">patients</span>
###xml 713 721 <span type="species:ncbi:9606">patients</span>
We therefore attempted to identify subgroups in which the effect of the TP53 codon 72 was more significant. A recent study showed that breast cancer patients with the Pro/Pro genotype demonstrated less sensitivity to a neoadjuvant chemotherapy regimen that included 5-FU, cyclophosphamide, and the anthracycline derivative pirarubicin [17]. This suggested that TP53 codon 72 polymorphism might be a strong predictive marker for chemotherapy response in breast cancer patients. Our data show that the Pro/Pro genotype was associated with poor DFS in node-positive but not in node-negative patients, and 76% of node-positive patients in our series had received adjuvant chemotherapy while only 26% of node-negative patients had.
###end p 47
###begin p 48
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 353 358 353 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 658 663 658 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 832 837 832 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1039 1044 1039 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1110 1112 1110 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 502 510 <span type="species:ncbi:9606">patients</span>
###xml 583 591 <span type="species:ncbi:9606">patients</span>
###xml 748 756 <span type="species:ncbi:9606">patients</span>
###xml 958 966 <span type="species:ncbi:9606">patients</span>
###xml 1079 1087 <span type="species:ncbi:9606">patients</span>
Although lymph node status is an important factor in classical staging of breast cancer based on histological/anatomical markers, there is little evidence that breast cancers with lymph node involvement are biologically different from those without it [32-34]. We therefore considered that the apparent effect of node status on the relationship between TP53 genotype and node status was due to a correlation between codon 72 polymorphism and effect of adjuvant chemotherapy, since 76% of node-positive patients in our series had received such therapy while only 26% of node-negative patients had. We thus analyzed breast cancer survival with respect to this TP53 polymorphism and the type of adjuvant therapy administered. Our data show that among patients who had received adjuvant chemotherapy, those with the Pro/Pro genotype of TP53 exhibited poorer DFS. Our finding is also consistent with a previous study of head and neck carcinoma showing that among patients who had received chemo-radiotherapy, those with the Pro/Pro genotype of TP53 showed poorer survival compared to patients with other genotypes [11].
###end p 48
###begin p 49
###xml 100 105 100 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 164 173 164 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 342 347 342 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 573 575 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 612 621 612 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 841 846 841 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 958 963 958 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1185 1190 1185 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1296 1301 1296 1301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1449 1451 1449 1451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1499 1504 1499 1504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1557 1559 1557 1559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1633 1638 1633 1638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1748 1753 1748 1753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
###xml 289 294 <span type="species:ncbi:9606">human</span>
###xml 646 654 <span type="species:ncbi:9606">patients</span>
###xml 732 740 <span type="species:ncbi:9606">patients</span>
###xml 877 885 <span type="species:ncbi:9606">patients</span>
###xml 1003 1011 <span type="species:ncbi:9606">patients</span>
###xml 1258 1266 <span type="species:ncbi:9606">patients</span>
###xml 1662 1670 <span type="species:ncbi:9606">patients</span>
###xml 1779 1787 <span type="species:ncbi:9606">patients</span>
Moreover, in ovarian cancer patients who received adjuvant cisplatinum/paclitaxel chemotherapy, the TP53 Pro allele was associated with a poorer prognosis [35]. An in vitro study showed that anticancer agents such as doxorubicin, 5-FU, and cisplatin induced a higher level of apoptosis in human H1299 cells expressing the Arg/Arg genotype of TP53 codon 72 than in those expressing the Pro/Pro genotype [11]. In addition, in a colony-survival assay, doxorubicin and cisplatin were more cytotoxic to cells expressing the Arg variant than to those expressing the Pro variant [11]. Our data are consistent with this in vitro study. The results among patients receiving both chemotherapy and hormonal therapy were similar to those among patients who had received adjuvant chemotherapy alone (data not shown), but no correlation was found between TP53 polymorphism and DFS among the patients receiving adjuvant hormonal therapy alone. Positive correlation between TP53 polymorphism and DFS was observed among patients receiving any chemotherapeutic agents. Since these compounds are cytotoxic while hormonal therapeutic agents are cytostatic, our results may reflect differential effects of TP53 polymorphism on different apoptotic pathways. Recently, ER positive patients possessing the Pro allele of TP53 codon 72 have been reported to show better distant recurrence-free survival when randomized to tamoxifen compared to those not receiving tamoxifen [18]. That report suggested that the Pro allele of TP53 codon 72 might be a predictor of tamoxifen response [18], although the authors did not present a Kaplan-Meier analysis of DFS by TP53 codon 72 genotype among patients receiving tamoxifen. We did not find any correlation between the genotype of TP53 codon 72 and prognosis in patients receiving tamoxifen alone (data not shown).
###end p 49
###begin p 50
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 310 317 310 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 401 406 401 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 591 596 591 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 650 655 650 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 726 731 726 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 819 821 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 863 868 863 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 985 990 985 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1076 1078 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1079 1081 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1179 1181 1179 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1182 1184 1182 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1196 1201 1196 1201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1286 1291 1286 1291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 234 242 <span type="species:ncbi:9606">patients</span>
###xml 783 791 <span type="species:ncbi:9606">patients</span>
###xml 945 953 <span type="species:ncbi:9606">patients</span>
###xml 1066 1074 <span type="species:ncbi:9606">patients</span>
Neither did we find any statistically significant association between MDM2 SNP309 and survival in any subgroups or in the total population, although we did observe a non-significant tendency toward better DFS with the T/T genotype in patients who received adjuvant tamoxifen with or without LH-RH analog. Bond et al. [28] proposed a model in which an estrogen-signaling pathway allows the G-allele of MDM2 SNP309 to accelerate breast cancer formation. This allele might also alter the efficacy of tamoxifen, although the mechanism is unclear. A recent report showed that the G/G genotype of MDM2 SNP309 was associated with poor prognosis, as well as TP53 mutations and p53 protein immunopositivity, in gastric carcinoma [36]. TP53 alteration is correlated with shortened survival of patients with gastric carcinoma [37,38]. This suggests that the G/G genotype of MDM2 SNP309 might, therefore, be predictive of poor survival in gastric carcinoma patients. Many reports demonstrate that TP53 mutations confer a worse overall and disease-free survival in breast cancer patients [39,40], while the prognostic value of p53 protein accumulation has not been consistently demonstrated [41,42]. Although TP53 mutation status was not available in our series, we analyzed the correlation between MDM2 SNP309 and p53-immunopositivity, but did not find any association between them.
###end p 50
###begin p 51
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 339 344 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 444 449 444 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 490 495 490 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 138 146 <span type="species:ncbi:9606">patients</span>
###xml 208 216 <span type="species:ncbi:9606">patients</span>
###xml 407 415 <span type="species:ncbi:9606">patients</span>
In previous reports, the frequency of the Pro/Pro genotype of TP53 codon 72 was about 7% to 30% [13,15,17,18,23,43,44], although 39.1% of patients with signet ring cell gastric carcinomas and 37.7% of female patients with lung carcinomas had the Pro/Pro genotype in subgroup analyses [15,44]. The reported frequency of the G/G genotype of MDM2 SNP309 is about 10% to 30% [23-28,36,43]. We found that 38% of patients had the Pro/Pro genotype of TP53 codon 72 and 33% had the G/G genotype of MDM2 SNP309. Therefore, the allelic discrimination data from TaqMan SNP genotyping assays were confirmed by direct sequencing of representative PCR products.
###end p 51
###begin p 52
###xml 306 311 306 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 211 219 <span type="species:ncbi:9606">patients</span>
One of the goals of translational cancer research is to identify molecular predictors of chemotherapy treatment. Molecular genetic determinants of treatment outcome are important to facilitate identification of patients most likely to benefit from chemotherapy. The present results suggest that the SNP of TP53 codon 72 is a potentially useful marker. However, this is a retrospective pilot study. Further work will be needed to verify the effect of this SNP in breast cancer.
###end p 52
###begin title 53
Conclusion
###end title 53
###begin p 54
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 232 240 <span type="species:ncbi:9606">patients</span>
The genotypes of TP53 codon 72 and MDM2 SNP309 were defined among 557 primary Japanese breast cancer patients. Our data show that the Pro/Pro genotype of TP53 codon 72 appears to be an independent prognostic marker in breast cancer patients.
###end p 54
###begin title 55
Abbreviations
###end title 55
###begin p 56
DFS = disease-free survival; ER = estrogen receptor; FU = fluorouracil; LH-RH = luteinizing hormone-releasing hormone; SNP = single-nucleotide polymorphism.
###end p 56
###begin title 57
Competing interests
###end title 57
###begin p 58
The authors declare that they have no competing interests.
###end p 58
###begin title 59
Authors' contributions
###end title 59
###begin p 60
###xml 226 234 <span type="species:ncbi:9606">patients</span>
TT conceived the design, carried out genotyping assays and drafted the manuscript. ZZ carried out genotyping assays and DNA sequencing. MN carried out genotyping assays. MH performed the statistical analysis. NK collected the patients' data. H Iwase and ST provided study material. H Iwata participated in the study design. HY participated in the study design. YF supported the study financially. All authors read and approved the final manuscript.
###end p 60
###begin title 61
Acknowledgements
###end title 61
###begin p 62
This work was supported by Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, grant #18390381.
###end p 62
###begin article-title 63
Surfing the p53 network
###end article-title 63
###begin article-title 64
###xml 18 28 <span type="species:ncbi:111938">gatekeeper</span>
p53, the cellular gatekeeper for growth and division
###end article-title 64
###begin article-title 65
The p53-Mdm2 module and the ubiquitin system
###end article-title 65
###begin article-title 66
Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53
###end article-title 66
###begin article-title 67
Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas
###end article-title 67
###begin article-title 68
Abnormal expression of MDM-2 in breast carcinomas
###end article-title 68
###begin article-title 69
###xml 107 115 <span type="species:ncbi:9606">patients</span>
Immunohistochemical status of p53, MDM2, bcl2, bax, and ER in invasive ductal breast carcinoma in Tunisian patients
###end article-title 69
###begin article-title 70
###xml 59 64 <span type="species:ncbi:9606">human</span>
Primary structure polymorphism at amino acid residue 72 of human p53
###end article-title 70
###begin article-title 71
The codon 72 polymorphic variants of p53 have markedly different apoptotic potential
###end article-title 71
###begin article-title 72
Two polymorphic variants of wild-type p53 differ biochemically and biologically
###end article-title 72
###begin article-title 73
###xml 65 74 65 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 78 85 78 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo
###end article-title 73
###begin article-title 74
p53 polymorphic variants at codon 72 exert different effects on cell cycle progression
###end article-title 74
###begin article-title 75
###xml 14 22 <span type="species:ncbi:9606">patients</span>
Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival
###end article-title 75
###begin article-title 76
###xml 161 169 <span type="species:ncbi:9606">patients</span>
Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients
###end article-title 76
###begin article-title 77
###xml 51 59 <span type="species:ncbi:9606">patients</span>
p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis
###end article-title 77
###begin article-title 78
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Genotype phenotype correlations in Israeli colorectal cancer patients
###end article-title 78
###begin article-title 79
###xml 90 98 <span type="species:ncbi:9606">patients</span>
p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer
###end article-title 79
###begin article-title 80
###xml 92 100 <span type="species:ncbi:9606">patients</span>
p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients
###end article-title 80
###begin article-title 81
p53 polymorphisms and haplotypes in breast cancer
###end article-title 81
###begin article-title 82
Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium
###end article-title 82
###begin article-title 83
###xml 133 139 <span type="species:ncbi:9606">humans</span>
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans
###end article-title 83
###begin article-title 84
A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells
###end article-title 84
###begin article-title 85
The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma
###end article-title 85
###begin article-title 86
Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status
###end article-title 86
###begin article-title 87
Association of breast cancer outcome with status of p53 and MDM2 SNP309
###end article-title 87
###begin article-title 88
No association between the MDM2-309 T/G promoter polymorphism and breast cancer in African-Americans or Whites
###end article-title 88
###begin article-title 89
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer
###end article-title 89
###begin article-title 90
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner
###end article-title 90
###begin article-title 91
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up
###end article-title 91
###begin article-title 92
Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer
###end article-title 92
###begin article-title 93
Genotyping of single nucleotide polymorphisms in cytokine genes using real-time PCR allelic discrimination technology
###end article-title 93
###begin article-title 94
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
###end article-title 94
###begin article-title 95
Repeated observation of breast tumor subtypes in independent gene expression data sets
###end article-title 95
###begin article-title 96
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival
###end article-title 96
###begin article-title 97
TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer
###end article-title 97
###begin article-title 98
MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis
###end article-title 98
###begin article-title 99
###xml 76 81 <span type="species:ncbi:9606">human</span>
p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma
###end article-title 99
###begin article-title 100
###xml 111 131 111 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Helicobacter pylori </italic>
###xml 111 130 <span type="species:ncbi:210">Helicobacter pylori</span>
p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis
###end article-title 100
###begin article-title 101
Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis
###end article-title 101
###begin article-title 102
###xml 59 67 <span type="species:ncbi:9606">patients</span>
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer
###end article-title 102
###begin article-title 103
Prognostic value of the immunohistochemical expression of p53 in breast carcinomas
###end article-title 103
###begin article-title 104
###xml 166 171 <span type="species:ncbi:9606">human</span>
Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors
###end article-title 104
###begin article-title 105
p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome
###end article-title 105
###begin article-title 106
A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer
###end article-title 106

